doc_id,table_id,row_index,ColumnA,ColumnB,ColumnC,ColumnD,ColumnE
WHO_TB_handbook_module5_pediatrics_2022,Table 5.8.,1,Weight band (kg),Isoniazid (H) (Intensive and continuation phase),Rifapentine (P) (Intensive and continuation phase),Moxifloxacin (M) (Intensive and continuation phase),Pyrazinamide (Z) (Intensive phase only)
WHO_TB_handbook_module5_pediatrics_2022,Table 5.8.,2,40–<50,300 mg,1200 mg,400 mg,1500-1600 mg (Dose depends on use of Z 400 mg or 500 mg tablets.)
WHO_TB_handbook_module5_pediatrics_2022,Table 5.8.,3,50–<65,,,,1500-1600 mg (Dose depends on use of Z 400 mg or 500 mg tablets.)
WHO_TB_handbook_module5_pediatrics_2022,Table 5.8.,4,≥65,,,,2000 mg